Although extensive indirect evidence exists to suggest that the central dopaminergic system plays a significant role in the modulation of arousal, the functional effect of the dopaminergic influence on the regulation of the sleep-wake cycle remains unclear. Thirteen healthy volunteers and 15 unmedicated subjects with a history of major depressive disorder underwent catecholamine depletion (CD) using oral alpha-methyl-para-tyrosine in a randomized, placebo-controlled, double-blind, crossover study. The main outcome measures in both sessions were sleepiness (Stanford-Sleepiness-Scale), cerebral glucose metabolism (positron emission tomography), and serum prolactin concentration. CD consistently induced clinically relevant sleepiness in both groups. The CD-induced prolactin increase significantly correlated with CD-induced sleepiness but not with CD-induced mood and anxiety symptoms. CD-induced sleepiness correlated with CD-induced increases in metabolism in the medial and orbital frontal cortex, bilateral superior temporal cortex, left insula, cingulate motor area and in the vicinity of the periaqueductal gray. This study suggests that the association between dopamine depletion and sleepiness is independent of the brain reward system and the risk for depression. The visceromotor system, the cingulate motor area, the periaqueductal gray and the caudal hypothalamus may mediate the impact of the dopaminergic system on regulation of wakefulness and sleep.
Introduction
Excessive daytime sleepiness (EDS) is of high clinical and public health importance. Excessive sleepiness has been implicated in approximately 16% of motor vehicle accidents, up to 50% of workrelated accidents and up to 25% of home-based accidents (Léger, 1994; Horne and Reyner, 1995) . EDS has also been associated with psychiatric and medical conditions (Hasler et al., 2005) . However, despite its high importance, the neurobiology of EDS is not well understood.
A variety of indirect evidence suggests that the central dopaminergic system plays a major role in sleep-wake regulation. The wake-promoting effect of amphetamine-like stimulants and modafinil has been associated with modulation of the dopaminergic system (Boutrel and Koob, 2004; Qu et al., 2008) , and sleepiness in subjects with Parkinson's disease has been associated with dysfunction of the dopaminergic system (Rye and Jankovic, 2002). Additionally, common sleep pathways in simple organisms such as Drosophila have involved dopamine (Andretic et al., 2005) . Despite this indirect evidence, it has been difficult to substantiate the mechanistic role of dopamine in sleep-wake regulation in higher mammals. Dopaminergic cells in the substantia nigra pars compacta (SNc) and the ventral tegmental area (VTA) do not change their mean firing rate across the sleep-wake cycle (Trulson et al., 1981) , and it has been proposed that these dopaminergic neurons play a role in the maintenance of behavioral arousal but not in the sleep-wake regulation itself (Jones et al., 1973) . Recently, however, wake-active dopaminergic neurons have been identified in the ventral periaqueductal gray matter (Lu et al., 2006a) and in the caudal hypothalamus (Léger et al., 2010) where dopamine cells are known to regulate prolactin levels (Moore, 1987) . These cells have extensive reciprocal connections with sleepwake regulation and endocrine systems and thus may support an ascending dopaminergic waking influence (McCarley, 2007) .
An instructive paradigm for investigating the relationship between catecholaminergic function and sleepiness more directly in humans involves the behavioral and neural response to catecholamine depletion (CD), achieved by administering alpha-methyl-paratyrosine (AMPT; (Berman et al., 1999; Hasler et al., 2004) , a competitive inhibitor of the rate-limiting enzyme in catecholamine synthesis, tyrosine hydroxylase (Nagatsu et al., 1964) . AMPT-administration decreases catecholamine transmission by depleting central dopamine and norepinephrine stores, as evidenced by reduced concentrations of catecholamines and their metabolites in plasma, urine and cerebrospinal fluid (Mignot and Laude, 1985; Stine et al., 1997) , and by directly measuring the effects of AMPT with dopaminergic imaging agents (Laruelle et al., 1997; Abi-Dargham et al., 2000; Verhoeff et al., 2003; Riccardi et al., 2008; Martinez et al., 2009) . Previous studies on catecholamine depletion consistently demonstrated the occurrence of sleepiness 24 hours after the first administration of AMPT in both healthy volunteers (McCann et al., 1992; Laruelle et al., Psychiatry Research: Neuroimaging 194 (2011) 73-78 
